Business Description
Ironwood Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US46333X1081
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.17 | |||||
Equity-to-Asset | -0.81 | |||||
Debt-to-Equity | -1.99 | |||||
Debt-to-EBITDA | 5.27 | |||||
Interest Coverage | 3.79 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -3.01 | |||||
Beneish M-Score | -4.51 | |||||
WACC vs ROIC |
Growth Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 5.5 | |||||
3-Year FCF Growth Rate | 4.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.86 | |||||
9-Day RSI | 47.19 | |||||
14-Day RSI | 44.36 | |||||
6-1 Month Momentum % | -51.17 | |||||
12-1 Month Momentum % | -49.94 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.92 | |||||
Quick Ratio | 3.92 | |||||
Cash Ratio | 2.32 | |||||
Days Sales Outstanding | 91.63 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 0.9 | |||||
Shareholder Yield % | -25.05 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | 31.56 | |||||
Net Margin % | 2.3 | |||||
FCF Margin % | 36.5 | |||||
ROE % | Neg. Equity | |||||
ROA % | 1.89 | |||||
ROIC % | 2.36 | |||||
3-Year ROIIC % | 10.07 | |||||
ROC (Joel Greenblatt) % | 181.12 | |||||
ROCE % | 46.94 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 113 | |||||
Forward PE Ratio | 9.11 | |||||
PE Ratio without NRI | 41.09 | |||||
Price-to-Owner-Earnings | 6.71 | |||||
PS Ratio | 1.86 | |||||
Price-to-Free-Cash-Flow | 5.04 | |||||
Price-to-Operating-Cash-Flow | 5.03 | |||||
EV-to-EBIT | 10.52 | |||||
EV-to-EBITDA | 10.34 | |||||
EV-to-Revenue | 3.14 | |||||
EV-to-FCF | 8.59 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Price-to-Median-PS-Value | 0.37 | |||||
Earnings Yield (Greenblatt) % | 9.51 | |||||
FCF Yield % | 20.27 |